AMS Unveils PredictDx

AMS Unveils PredictDx

Advanced Medical Strategies experiences rapid subscriber growth for PredictDx   PredictDx gives Health Care Payors, Carriers and Reinsurers unprecedented web access to clinical and financial details of 150+ diagnoses Advanced Medical Strategies has changed the way carriers, reinsurers, MGU’s, TPA’s, and Brokers predict and manage costs associated with trigger diagnoses. Advanced Medical Strategies’ PredictDx is a new, patent pending software as a service (SAAS) subscription based offering. PredictDx details costs, risks, accepted treatments and other information related to more than…

Read More Read More

Claims Auditing

Claims Auditing

Don’t miss a thing. AMS claims audits are performed by experienced professionals that ensure the completeness and accuracy of every claim before adjudication.

Clinical

Clinical

Gaining a clinical perspective means gaining possibilities, comprehension, and strategy. Without a clinical overview, there are missed opportunities to reach the best outcome. AMS physician-led reviews and reporting give you a fuller picture of how treatments relate to costs.

Cost Containment

Cost Containment

Find savings strategies for Bill Audits, Negotiations, and Reference based Pricing. AMS offers their complete services to find where your claims costs can be reduced.

Directories

Directories

AMS puts a “Physician in your pocket” with a digital library of clinically reviewed treatments or pharmaceuticals. Find and compare costs, treatment details, and risk analyses by using these searchable applications.

Orenitram for Pulmonary Arterial Hypertension

Orenitram for Pulmonary Arterial Hypertension

  United Therapeutics announced that the FDA has approved Orenitram (treprostinil) extended-release tablets for the treatment of pulmonary arterial hypertension (PAH) in WHO Group I patients to improve exercise capacity. RELATED: Cardiovascular Disease Resource Center The approval was based on data from FREEDOM-M, the primary efficacy study that included patients with WHO functional class II to III symptoms and etiologies of idiopathic of idiopathic or heritable PAH or PAH associated with connective tissue disease. Results showed that patients receiving Orenitram improved their median…

Read More Read More

Tretten Approved for Genetic Clotting Disorder

Tretten Approved for Genetic Clotting Disorder

  The FDA has approved Tretten (coagulation factor XIII A-subunit [recombinant]; Novo Nordisk) for use in the routine prevention of bleeding in adults and children who have congenital Factor XIII A-subunit deficiency, a rare clotting disorder. Tretten is the first recombinant product approved for this indication. RELATED: Hematological Disorders Resource Center Tretten is a recombinant analog of the human Factor XIII A-subunit that is produced in yeast cells and then further purified. It is a sterile freeze-dried powder that is reconstituted for…

Read More Read More

Nexavar to treat type of thyroid cancer

Nexavar to treat type of thyroid cancer

originally posted on FDA.gov FDA approves Nexavar to treat type of thyroid cancer The U.S. Food and Drug Administration today expanded the approved uses of Nexavar (sorafenib) to treat late-stage (metastatic) differentiated thyroid cancer. Thyroid cancer is a cancerous growth of the thyroid gland, which is located in the neck. Differentiated thyroid cancer is the most common type of thyroid cancer. The National Cancer Institute estimates that 60,220 Americans will be diagnosed with thyroid cancer and 1,850 will die from…

Read More Read More

FDA approves Imbruvica for rare blood cancer

FDA approves Imbruvica for rare blood cancer

originally posted on FDA.gov FDA approves Imbruvica for rare blood cancer Second drug with breakthrough therapy designation to receive FDA approval   The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. MCL is a rare form of non-Hodgkin lymphoma and represents about 6 percent of all non-Hodgkin lymphoma cases in the United States. By the time MCL is diagnosed, it usually has already…

Read More Read More

Johnson & Johnson false drug marketing

Johnson & Johnson false drug marketing

Johnson & Johnson will pay $2.2 billion to settle charges that the company marketed drugs for unapproved uses and paid “kickbacks” to doctors and nursing homes.     Originally published by CNNMoney, Nov 4th The penalties announced Monday involve fines and forfeiture to the federal government and several states. The settlement involves the schizophrenia drugs Risperdal and Invega, and the heart failure drug Natrecor, the company and Attorney General Eric Holder said. Johnson & Johnson and two subsidiaries “lined their…

Read More Read More